Introduction
Microvolt T wave alternans detection is a recentlydeveloped non-invasive technique which assesses global electrophysiological remodelling of the left ventricle, manifest as minor beat-to-beat changes in repolarisation, and is the most powerful non-invasive marker of ventricular tachyarrhythmia and sudden death risk. [1] [2] [3] The T-wave alternations are small in amplitude (microvolts) in comparison to the size of the T wave itself (millivolt), and so specialised electrodes and software are required for their detection on treadmill and bicycle exercise. Exaggeration of this phenomenon during exercise in various patient groups, including dilated and hypertrophic cardiomyopathies and ischaemic and non-ischaemic heart failure, is associated with these risks. [1] [2] [3] [4] [5] [6] In some settings, such as chronic heart failure, the presence of T wave alternans is a strong predictor of sudden cardiac death, and its prognostic power may exceed that of conventional electrophysiological testing. 2, 3 Our current best understanding is that T wave alternans occurs when the combination of heart rate and workload result in small areas of myocardium failing to complete their refractory periods during a single cardiac cycle length, so that they are only available for depolarisation, and therefore repolarisation, on alternate beats. 1, 3, 5 Variations in depolarisation are difficult to see due to the frequency characteristics of the QRS, but alternation in the repolarisation vector can be detected in the Twave.
In hypertension, left ventricular hypertrophy (LVH) is established as an independent risk factor Correspondence: Nicholas Peters, Professor of Clinical Electrophysiology, Department of Cardiology, St Mary's Hospital, Paddington, London W2 1NY, UK. E-mail: n.petersȰic.ac.uk for subsequent cardiovascular events and specifically arrhythmic death. One potential mechanism for this is that the thickened myocardium outgrows its blood supply so that there are numerous areas of supply-demand mismatch. This is a situation in which repolarisation abnormalities are likely (as is seen in conventional exercise ECG testing of patients with LVH) and would be expected to be a substrate for the development of T wave alternans. There is little information in respect of reactive ventricular hypertrophy in the published literature, but high-risk patients with hypertrophic cardiomyopathy often show T-wave alternans. The aim of this sub-study is to address the hypothesis that microvolt T-wave alternans does occur in hypertensive LVH, resolves with resolution of LVH with appropriate antihypertensive treatment, and that these changes correlate with arrhythmic threshold. In order to avoid potential confounding influences of substantial changes in blood pressure and drug administration, this study will be conducted on patients already established on, and then after an extended period of receiving, effective antihypertensive treatment.
Objectives
Our principal aim is to describe the T wave alternans behaviour in patients with hypertension and LVH. Our secondary aim is to observe the effect of long-term treatment (aimed at inducing regression of ventricular hypertrophy) on alternans physiology, and how this may influence arrhythmia count and, although not specifically powered for this, clinical events.
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Methods
Patients are asked to exercise on a bicycle while the ECG is monitored using high-resolution electrodes capable of resolving voltages at the microvolt level. An automatic algorithm continuously computes the size of any beat-to-beat alternation in the T wave amplitude of the vector ECG. Fourier analysis is used to quantify the alternans and compare it with the size of random background fluctuations. The test result is positive if beat-to-beat alternation is present and clearly distinguishable from the low-level nonalternans background noise. The exercise itself takes 5-15 min (depending on patient fitness) and together with attachment and removal of ECG electrodes and paperwork, the entire visit will take 30-40 mins.
For the purposes of this study we are assuming a prevalence of 30% in the ASCOT patient population (based on prevalence data in other patient groups, see below). If initial recruitment of the first 30 patients confirms adequate prevalence, we aim to recruit at least 100 patients from the ASCOT study (taking part in the phenotype sub-study, to include echocardiographic LV form and functional assessment) and 100 healthy controls, matched for age, sex and ethnic origin. The ASCOT patients will undergo T wave alternans testing and 24-h Holter arrhythmia monitoring early in their treatment, and again after approximately 1 year, on visits coordinated to coincide with routine ASCOT visits. This will allow us to examine the effect of LVH and good long-term control of their cardiovascular risk profile on their T wave alternans physiology and arrhythmia count.
Full written informed consent will be obtained and local ethical approval, for which no problem is anticipated, is pending.
Statistical methodology
The simplest outcome measure is the presence or absence of T wave alternans. Using an assumed prevalence of 30% in the patient population (ie conservatively selecting a lower rate than the 40-60% reported for heart failure patients and patients clinically referred for arrhythmia risk evaluation) and 5% in the age-matched control population (higher than the 0-1% seen in previous work in normals), a study size of 70 would give an 80% power to detect the difference at the conventional 5% significance level. We would seek to recruit 200 subjects in total (100 ASCOT and 100 healthy controls) which would give a margin of safety in case the prevalence is lower than expected in the patients, and would give us the opportunity to examine subgroups usefully.
A second aspect of the data that we will compare is the heart rate at which alternans becomes positive. This can be considered nonparametrically (with alternans-negative patients placed at one extreme) which would allow us to compare the threshold for alternans even if peak achieved heart rates differed between groups.
Inclusion criteria: Patients with hypertension and echocardiographic LVH without angina, satisfying the criteria for the ASCOT study.
Exclusion criteria: Unwillingness to perform bicycle exercise, atrial fibrillation, left bundle branch block and severe musculoskeletal disease preventing bicycle exercise
Discussion
This is a noninvasive test requiring only simple bicycle exercise, under full medical supervision. This type of exercise is known to be safe and is a routine part of clinical assessment of patients with chronic systolic heart failure (for example), the majority of whom have underlying ischaemic heart disease, and therefore should pose no problems for the ASCOT population who have good systolic cardiac function and do not have clinical ischaemic heart disease.
T wave alternans has proven to be the strongest non-invasive marker for arrhythmic risk. Hypertensive LVH is also an important independent risk factor for arrhythmic risk. With this study we have the potential of identifying a mechanistically relevant marker of arrhythmic risk which is easily measured and may be a clinically useful parameter to assess arrhythmic risk during antihypertensive treatment.
